FDA Two new Q&As published for Investigational Drugs

Recommendation
18-20 November 2025
Heidelberg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
The U.S. Food and Drug Administration FDA has published two new Question and Answer Documents on Investigational Drugs.
One of the draft Guidance for Industry documents is intended to provide information for industry, researchers, and physicians about the implementation of FDA's regulation on charging for investigational drugs under an Investigational New Drug Application (IND) (21 CFR 312.8). The other one is intended to provide information about the implementation of FDA's regulations on expanded access to investigational drugs for treatment use under an investigational new drug application (IND) (21 CFR part 312, subpart I).
Both documents are being distributed for comment purposes only.
Related GMP News
10.07.2025EMA Policy on the Publication of Clinical Data
17.06.2025EMA Implementation of ICH E6, M11 & M12
03.04.2025Update on the ICH M11 CeSHArP Technical Specification
03.04.2025EU Map to Clinical Trials
03.04.2025EMA Concept Paper on Model Informed Drug Development